A blood-based predictor for neocortical Aβ burden in Alzheimer’s disease: results from the AIBL study von Burnham, S C, Faux, N G, Wilson, W, Laws, S M, Ames, D, Bedo, J, Bush, A I, Doecke, J D, Ellis, K A, Head, R, Jones, G, Kiiveri, H, Martins, R N, Rembach, A, Rowe, C C, Salvado, O, Macaulay, S L, Masters, C L, Villemagne, V L

Volltext

Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment von Cheng, L, Doecke, J D, Sharples, R A, Villemagne, V L, Fowler, C J, Rembach, A, Martins, R N, Rowe, C C, Macaulay, S L, Masters, C L, Hill, A F

Volltext

Does type 2 diabetes influence the risk of oesophageal adenocarcinoma? von Neale, R E, Doecke, J D, Pandeya, N, Sadhegi, S, Green, A C, Webb, P M, Whiteman, D C

Volltext

Reduced α-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn’s disease von Simms, L A, Doecke, J D, Walsh, M D, Huang, N, Fowler, E V, Radford-Smith, G L

Volltext

Editorial: first among Equals—not for either infliximab or adalimumab in Crohn's disease—yet von Lim, M. H., Doecke, J. D., Radford‐Smith, G. L.

Volltext

Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study von Doecke, J. D., Hartnell, F., Bampton, P., Bell, S., Mahy, G., Grover, Z., Lewindon, P., Jones, L. V., Sewell, K., Krishnaprasad, K., Prosser, R., Marr, D., Fischer, J., R Thomas, G., Tehan, J. V., Ding, N. S., Cooke, S. E., Moss, K., Sechi, A., De Cruz, P., Grafton, R., Connor, S. J., Lawrance, I. C., Gearry, R. B., Andrews, J. M., Radford‐Smith, G. L.

Volltext

Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort – authors’ reply von Radford‐Smith, G. L., Hartnell, F., Doecke, J. D.

Volltext

A Conformational Variant of p53 (U-p53AZ) as Blood-Based Biomarker for the Prediction of the Onset of Symptomatic Alzheimer’s Disease von Piccirella, Simona, Van Neste, L., Fowler, C., Masters, C. L., Fripp, J., Doecke, J. D., Xiong, C., Uberti, D., Kinnon, P.

Volltext

Two-Year Prognostic Utility of Plasma p217+tau across the Alzheimer’s Continuum von Feizpour, A., Doré, V., Doecke, J. D., Saad, Z. S., Triana-Baltzer, G., Slemmon, R., Maruff, P., Krishnadas, N., Bourgeat, P., Huang, K., Fowler, C., Rainey-Smith, S. R., Bush, A. I., Ward, L., Robertson, J., Martins, R. N., Masters, C. L., Villemagne, V. L., Fripp, J., Kolb, H. C., Rowe, Christopher C.

Volltext

Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fl... von Lifke, Valeria, Kollmorgen, Gwendlyn, Manuilova, Ekaterina, Oelschlaegel, Tobias, Hillringhaus, Lars, Widmann, Monika, von Arnim, Christine A.F., Otto, Markus, Christenson, Robert H., Powers, Jennifer L., Shaw, Leslie M., Hansson, Oskar, Doecke, James D., Li, Qiao-Xin, Teunissen, Charlotte, Tumani, Hayrettin, Blennow, Kaj

Volltext

Method comparison study of the Elecsys® β-Amyloid (1–42) CSF assay versus comparator assays and LC-MS/MS von Shaw, Leslie M., Hansson, Oskar, Manuilova, Ekaterina, Masters, Colin L., Doecke, James D., Li, Qiao-Xin, Rutz, Sandra, Widmann, Monika, Leinenbach, Andreas, Blennow, Kaj

Volltext

Does type 2 diabetes influence the risk of oesophageal adenocarcinoma? von Neale, R E, Doecke, J D, Pandeya, N, Sadeghi, S, Green, A C, Webb, P M, Whiteman, D C

Volltext

Association of Functionally Different RUNX2 P2 Promoter Alleles With BMD von Doecke, James D, Day, Christopher J, Stephens, Alexandre SJ, Carter, Shea L, van Daal, Angela, Kotowicz, Mark A, Nicholson, Geoff C, Morrison, Nigel A

Volltext

Authors' reply von Simms, L A, Doecke, J D, Radford-Smith, G L

Volltext

Authors' reply von Simms, L A, Doecke, J D, Radford-Smith, G L

Volltext

Authors' reply von Simms, L A, Doecke, J D, Radford-Smith, G L

Volltext

A blood-based predictor for neocortical A[beta] burden in Alzheimer's disease: results from the AIBL study von Burnham, S C, Faux, N G, Wilson, W, Laws, S M, Ames, D, Bedo, J, Bush, A I, Doecke, J D, Ellis, K A, Head, R, Jones, G, Kiiveri, H, Martins, R N, Rembach, A, Rowe, C C, Salvado, O, Macaulay, S L, Masters, C L, Villemagne, V L

Volltext

Erratum: Does type 2 diabetes influence the risk of oesophageal adenocarcinoma? von Neale, R E, Doecke, J D, Pandeya, N, Sadeghi, S, Green, A C, Webb, P M, Whiteman, D C

Volltext

Reduced  -defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease von Simms, L A, Doecke, J D, Walsh, M D, Huang, N, Fowler, E V, Radford-Smith, G L

Volltext

Reduced oc-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease von SIMMS, L. A, DOECKE, J. D, WALSH, M. D, HUANG, N, FOWLER, E. V, RADFORD-SMITH, G. L

Volltext